BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30477535)

  • 1. Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?
    Gil-Martínez AL; Cuenca L; Sánchez C; Estrada C; Fernández-Villalba E; Herrero MT
    J Neuroinflammation; 2018 Nov; 15(1):328. PubMed ID: 30477535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
    Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
    Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
    Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
    Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
    Tripanichkul W; Sripanichkulchai K; Finkelstein DI
    Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
    Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
    Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson's disease in mice.
    Zhang G; Yang G; Liu J
    Life Sci; 2019 Sep; 232():116600. PubMed ID: 31251998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
    Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
    J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
    Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway.
    Churchill MJ; Pflibsen L; Sconce MD; Moore C; Kim K; Meshul CK
    Neuroscience; 2017 Sep; 359():224-247. PubMed ID: 28754312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.
    Martin HL; Santoro M; Mustafa S; Riedel G; Forrester JV; Teismann P
    Glia; 2016 Mar; 64(3):386-95. PubMed ID: 26511587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
    Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
    J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective Effect of Echinacoside in Subacute Mouse Model of Parkinson's Disease.
    Liang Y; Chen C; Xia B; Wu W; Tang J; Chen Q; Tang L; Yang H; Zhang Z; Lu Y; Yang Y; Zhao Y
    Biomed Res Int; 2019; 2019():4379639. PubMed ID: 30834264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage.
    Viveros-Paredes JM; Gonzalez-Castañeda RE; Escalante-Castañeda A; Tejeda-Martínez AR; Castañeda-Achutiguí F; Flores-Soto ME
    Neurologia (Engl Ed); 2019 Apr; 34(3):143-152. PubMed ID: 28104279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
    Fujita A; Yamaguchi H; Yamasaki R; Cui Y; Matsuoka Y; Yamada KI; Kira JI
    J Neuroinflammation; 2018 Aug; 15(1):227. PubMed ID: 30103794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease.
    Yu Q; Huang Q; Du X; Xu S; Li M; Ma S
    Exp Neurol; 2018 Apr; 302():145-154. PubMed ID: 29337144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.